Our own pharma editor, Brian Buntz, has won national gold in the 2023 Azbee Awards of Excellence. The accolade from the American Society of Business Publication Editors (ASBPE) recognized Buntz’s coverage for Drug Discovery & Development, which was highlighted in the sister print publication of Medical Design & Outsourcing. ASBPE is a widely recognized professional…
Science unbound: AI and open data accelerate the pace of discovery
Scientists have long been perceived and portrayed in film as old people in white lab coats perched at a bench full of bubbling fluorescent liquids. The present-day reality of scientific research is quite different from old stereotypes, with AI-driven scientific breakthroughs emerging as a major driving force behind new discoveries. Scientists are increasingly data jockeys…
Development challenges and regulatory changes for cell and gene therapies
Cell and gene therapies are the fastest growing area for drug development. The groundwork for this category was laid with the mapping of the human genome in 2003, and the field has developed rapidly in the intervening decades. These powerful therapies have significant potential for the treatment of cancer and other previously “undruggable” diseases. But…
FAQ: What are pharmacokinetics and pharmacodynamics?
Drug formulation involves balancing the body’s ability to use and then eliminate the drug candidate. The field of pharmacology is dedicated to this balancing act, studying how a drug candidate influences biological systems and the body’s reaction to that compound. This task involves the study of pharmacokinetics (PK) and pharmacodynamics (PD). Pharmacokinetics is the study…
OcuMedic, Gelest ink drug-delivering contact lens deal
OcuMedic said today that it entered into an exclusive supply agreement and picked up a strategic investment from Gelest for its proprietary drug-eluting soft contact lens of an undisclosed amount. Under the terms of the agreement, Morrisville, Pa.-based Gelest is set to manufacture and supply OcuMedic’s key chemistry components used in the controlled release of…
Intersect ENT’s Ascend study misses endpoint
Intersect ENT (NSDQ:XENT) shares plunged today after the company said it failed to meet the primary endpoint in a study of its Ascend investigational drug-coated sinus balloon. The 70-person, randomized, double-blind trial was designed to compared treatment with Intersect ENT’s DCB when randomized against an uncoated balloon control. The study missed the primary endpoint, frontal sinus…
FDA clears Insulet’s OmniPod Dash as insulin pump alternative
Insulet (NSDQ:PODD) said today that it won FDA clearance to market its Omnipod Dash alternate controller-enabled (ACE) infusion pump as an integrated insulin pump. The Acton, Mass.-based company received FDA 510(k) clearance for the Omnipod Dash in June 2018 and launched the device earlier this year. The latest indication states that the pump can reliably and…